Design and discovery of novel, potent pyrazinone-based thrombin inhibitors with a solubilizing amino P1-P2-linker

被引：6

作者：

Bulat, S. ^{[1
]}

Bosio, S. ^{[1
]}

Papadopoulos, M. A. ^{[1
]}

Cerezo-Galvez, S. ^{[1
]}

Grabowski, E. ^{[1
]}

Rosenbaum, C. ^{[1
]}

Matassa, V. G. ^{[1
]}

Ott, I. ^{[1
]}

Metz, G. ^{[1
]}

Schamberger, J. ^{[1
]}

Sekul, R. ^{[1
]}

Feurer, A. ^{[1
]}

机构：

[1] Santhera Pharmaceut Schweiz GmbH, CH-4410 Liestal, Switzerland

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2006年 / 3卷 / 05期

关键词：

thrombin; pyrazinone; X-ray; binding mode; selectivity;

D O I：

10.2174/157018006777574203

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The evolution of a novel class of pyrazinone direct thrombin inhibitors (DTIs) is described. In an effort to improve the solubility and thereby the drug-like properties of pyrazinones that possess non-basic P, residues, a novel amino P-1-P-2 linker has been designed from X-ray thrombin-inhibitor complexes. Biochemical evaluation demonstrated that nanomolar binding affinity was attained, and X-ray co-crystal structures reveal an unprecedented binding mode that involves an interaction of the new amino linker with Glu192 of the active site of thrombin. A family of soluble pyrazinones has thereby emerged.

引用

页码：289 / 292

页数：4

共 19 条

[11] Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: Preference for a neutral group in the S1 pocket [J].

Maignan, S ;

Guilloteau, JP ;

Choi-Sledski, YM ;

Becker, MR ;

Ewing, WR ;

Pauls, HW ;

Spada, AP ;

Mikol, V .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (05) :685-690

[12] Discovery of thrombin inhibitor fragments from chemical microarray screening [J].

Neumann, T ;

Junker, HD ;

Keil, O ;

Burkert, K ;

Ottleben, H ;

Gamer, J ;

Sekul, R ;

Deppe, H ;

Feurer, A ;

Tomandl, D ;

Metz, G .

LETTERS IN DRUG DESIGN & DISCOVERY, 2005, 2 (08) :590-594

[13]

Pfau R, 2003, CURR OPIN DRUG DISC, V6, P437

[14] Serine proteases as targets for antithrombotic therapy [J].

Ries, UJ ;

Wienen, W .

DRUGS OF THE FUTURE, 2003, 28 (04) :355-370

[15] Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939):: An oral, direct factor Xa inhibitor [J].

Roehrig, S ;

Straub, A ;

Pohlmann, J ;

Lampe, T ;

Pernerstorfer, J ;

Schlemmer, KH ;

Reinemer, P ;

Perzborn, E .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (19) :5900-5908

[16] L-373,890, an achiral, noncovalent, subnanomolar thrombin inhibitor [J].

Sanderson, PEJ ;

Dyer, DL ;

NaylorOlsen, AM ;

Vacca, JP ;

Gardell, SJ ;

Lewis, SD ;

Lucas, BJ ;

Lyle, EA ;

Lynch, JJ ;

Mulichak, AM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (12) :1497-1500

[17] Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates [J].

Sanderson, PEJ ;

Lyle, TA ;

Cutrona, KJ ;

Dyer, DL ;

Dorsey, BD ;

McDonough, CM ;

Naylor-Olsen, AM ;

Chen, IW ;

Chen, ZG ;

Cook, JJ ;

Cooper, CM ;

Gardell, SJ ;

Hare, TR ;

Krueger, JA ;

Lewis, SD ;

Lin, JH ;

Lucas, BJ ;

Lyle, EA ;

Lynch, JJ ;

Stranieri, MT ;

Vastag, K ;

Yan, YW ;

Shafer, JA ;

Vacca, JP .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (23) :4466-4474

[18] New advances in the discovery of thrombin and factor Xa inhibitors [J].

Vacca, JP .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2000, 4 (04) :394-400

[19] Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors [J].

Young, MB ;

Barrow, JC ;

Glass, KL ;

Lundell, GF ;

Newton, CL ;

Pellicore, JM ;

Rittle, KE ;

Selnick, HG ;

Stauffer, KJ ;

Vacca, JP ;

Williams, PD ;

Bohn, D ;

Clayton, FC ;

Cook, JJ ;

Krueger, JA ;

Kuo, LC ;

Lewis, SD ;

Lucas, BJ ;

McMasters, DR ;

Miller-Stein, C ;

Pietrak, BL ;

Wallace, AA ;

White, RB ;

Wong, B ;

Yan, YW ;

Nantermet, PG .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (12) :2995-3008

← 1 2 →